RIVA-LATANOPROST SOLUTION

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

LATANOPROST

متاح من:

LABORATOIRE RIVA INC.

ATC رمز:

S01EE01

INN (الاسم الدولي):

LATANOPROST

جرعة:

50MCG

الشكل الصيدلاني:

SOLUTION

تركيب:

LATANOPROST 50MCG

طريقة التعاطي:

OPHTHALMIC

الوحدات في الحزمة:

2.5ML

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

PROSTAGLANDIN ANALOGS

ملخص المنتج:

Active ingredient group (AIG) number: 0132916002; AHFS:

الوضع إذن:

APPROVED

تاريخ الترخيص:

2012-01-27

خصائص المنتج

_RIVA-LATANOPROST (latanoprost) _
_Page 1 de 26 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
RIVA-LATANOPROST
Latanoprost ophthalmic solution
Solution, 50 mcg/mL, Ophthalmic
Prostaglandin F
2α
analogue
Date of Initial Authorization:
JAN
27, 2012
Date of Revision:
OCT
25, 2023
LABORATOIRE RIVA INC.
660 Boul. Industriel
Blainville, Quebec
J7C 3V4
www.labriva.com
Submission Control Number: 279978
_RIVA-LATANOPROST (latanoprost) _
_Page 2 de 26 _
RECENT MAJOR LABEL CHANGES
None at the time of most recent authorization
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.................................................................................
4
4.1
Dosing Considerations
..............................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
......................................................... 4
4.4
Administration
..........................................................................................................
5
4.5
Missed Dose
.......................................